Gene Therapy With Lentivirus Is Acceptable For Clinical Trials, ICH Panel Says
Executive Summary
Lentiviral vectors are acceptable for use in human clinical trials but the safety studies required will depend on the patient population and disease indication under study, an International Conference on Harmonization workgroup said Sept. 9 during a gene therapy workshop in Vienna, Va
You may also be interested in...
Viral Vector-Assisted Gene Therapy Safer Than Ever, Experts Say As FDA Prepares For Advisory Panel
Replication-competent retrovirus and lentivirus appear less threatening than they once did.
VirxSys Lentivirus IND For HIV Will Be Filed By First Quarter of 2002
VirxSys is planning to submit an investigational new drug application for its HIV-1 lentiviral vector for treatment of patients infected with HIV by the first quarter of 2002
Adenovirus Vector Standards Should Be Loosened For Healthier Patients
FDA should loosen the standard for levels of replication-competent adenovirus in gene therapy products for all but the most severely immunocompromised patients, the Biological Response Modifiers Advisory Committee suggested July 13.